ReviewChinese neurosurgical journal2026
BBB-aware stimuli-responsive and biomimetic nanomedicines for glioblastoma.
Review in Chinese neurosurgical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) poses a tremendous challenge because it causes substantial morbidity and mortality. Treatment remains constrained by the tightly regulated blood-brain barrier (BBB) and the heterogeneous blood-brain tumor barrier (BBTB), which together severely limit drug delivery to tumor tissue. Nanomaterial-based drug delivery systems offer an opportunity to overcome the short half-life, low bioavailability, and poor BBB penetration that restrict conventional GBM therapeutics. Nanotechnology also provides safe, effective, and targeted drug delivery systems that enhance penetration, stability, and therapeutic efficacy. This review discusses biomaterials-based nanomedicine platforms for GBM, with a focus on lipid-based carriers, polymeric nanoparticles, dendrimers, inorganic nanomaterials, and biomimetic nanosystems designed to interact with the BBB/BBTB. We summarize how passive and active brain-targeting strategies are combined with endogenous and exogenous stimuli-responsive designs (pH/redox sensitivity, magnetic hyperthermia, photothermal/photodynamic therapy, and ultrasound-triggered systems) to enhance intratumoral accumulation and anti-GBM efficacy. Overall, this review discusses recent advances in BBB-aware, stimuli-responsive, and biomimetic nanomedicines for GBM, and outlines their therapeutic potential alongside persistent challenges in safety, large-scale manufacturing, and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.